Inflammatory Immunity Articles & Analysis
21 news found
Tofacitinib Citrate Tofacitinib Citrate is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by suppressing the immune system and reducing inflammation in the body. Tofacitinib Citrate is a selective inhibitor of Janus kinase (JAK) enzymes, which play a key role in immune response and ...
Creative Proteomics Cytokine recently launched the Mouse Cytokine Assay with high sensitivity to support research in immune responses, inflammatory diseases, allergies, sepsis, and cancer. Cytokines play an important role in physiological and pathological processes such as immune cell differentiation and subset development, ...
YM7555 delivers both genes, which code for the ABeta and TAU, to muscle cells where the corresponding peptide is then made. The immune system of the individual receiving the genes and making the peptides then makes antibodies against the peptides. ...
Cipla also recently launched a biosimilar for the treatment of immune-mediated inflammatory disease. According to the Cancer Alliance report CA03/2021, South Africa faces a crisis in terms of affordable access to medicines, particularly in the treatment of cancer. ...
SetPoint Medical’s bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. The company is developing a novel bioelectronic medicine platform designed to stimulate the vagus nerve to ...
“The amlitelimab data presented at EADV support our belief that OX40-Ligand has the potential to provide a novel approach to treating a range of immune-mediated diseases," said Naimish Patel, M.D. Head of Global Development in Immunology and Inflammation at Sanofi. ...
“SetPoint is reshaping the treatment paradigm of chronic inflammatory diseases with potentially less risk and lower cost than drug therapy,” says Rob Lake, Managing Director and Head of Life Sciences at Runway. ...
SetPoint Medical’s bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. The company is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate ...
In the NNCIT-02 study, brittle diabetes patients being transplanted with islets of Langerhans are treated with IBSOLVMIR® which has shown to be able to address the instant blood-mediated inflammatory reaction (IBMIR) occurring as an innate immune reaction to the infusion of transplanted cells. ...
SetPoint’s investigational bioelectronic medicine platform stimulates the vagus nerve to activate the endogenous inflammatory reflex and thereby reduce inflammation. The Company has received FDA Investigational Device Exemption (IDE) approval for a multicenter, double-blind, randomized, sham controlled pivotal trial that will enroll up to 250 patients at 40 clinical trial ...
” “These new data confirm that activation of the cholinergic anti-inflammatory pathway by vagus nerve stimulation can reduce disease activity even in patients who have failed to respond to multiple classes of biological drugs and JAK inhibitors,” said Dr. ...
” “These new data confirm that activation of the cholinergic anti-inflammatory pathway by vagus nerve stimulation can reduce disease activity even in patients who have failed to respond to multiple classes of biological drugs and JAK inhibitors,” said Dr. ...
SetPoint Medical’s bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. The company is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate ...
Ariana® Pharma a leading Artificial Intelligence drug development company announced today that it has entered into an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi and leading academic partners targeting autoimmune and inflammatory diseases associated with primary immune deficiencies. The ATRACTion project will generate ...
SetPoint Medical’s bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. The company is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate ...
SetPoint Medical’s bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. The company is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate ...
SetPoint Medical’s bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. The company is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate ...
Researchers from Boston Children’s Hospital and MIT took mini-antibodies from alpacas Bryson and Sanchez. Then they shrunk the mini-antibodies into even smaller nanobodies and engineered these nanobodies onto CAR-T cells. During this process, they discovered a new form of cell therapy. The goal is to enhance CAR-T cells’ targeting abilities by targeting immunosuppressive proteins in ...
ByIMAPAC
” While many novel approaches are still in early stages, it’s important to keep in mind that the first immune checkpoint inhibitor was approved only eight years ago, and only two years ago did we see the first-ever therapy approved based on genetics rather than tumor type, says Chad Clark, president of Precision for Medicine. ...
” “This new technology’s ability to include different cell types within a single extracellular matrix will make it possible to recreate a microtissue in which inflammatory response and tissue remodeling phenomena can be studied in vitro,” explained Hélène Aerts, in charge of Biologie Servier’s in vitro platform. ...
ByPoietis